Fig. 6
From: MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression
Inhibiting effect of miR-1307 ASO and Taxol by increasing ING5 in vivo. a and b The mice tumors volume in different groups. After 29 days of treatment, the miR-1307 ASO and/or Taxol therapy decreased the tumors volume compared to the MOCK group, and compared to the ASO con group, the average tumor volume in miR-1307 ASO and miR-1307 ASO + Taxol group was decreased significantly (P < 0.05 and P < 0.01, respectively). Besides, compared to the Taxol group, the average tumor volume in miR-1307 ASO + Taxol group was decreased significantly (P < 0.05). c Western Blot results of ING5 expression in different groups. ING5 expression was increased in the miR-1307 ASO and/or Taxol treated group in ovarian cancer cells injected tumor xenografts in nude mice, and its expression was higher in the miR-1307 ASO + Taxol treated group than that in the miR-1307 ASO treated group (P < 0.01). Results are representative of at least three separate experiments. Data are expressed as the mean ± standard deviation. Data from three experimental determinations and bars indicate the SD (*P < 0.05, **P < 0.01)